2022年3月12日 · Donor specific Antibodies (DSA) are one of the established biomarkers for predicting antibody mediated rejection (ABMR). This blog is a short synopsis on DSA and their complex characteristics in kidney transplantation. DSA may be preformed (before transplantation) or de-novo (developing after transplantation).

移植前预致敏患者体内的预存DSA（preformed DSA，pfDSA）可诱发超急性排斥反应、加速急性排斥反应和早期活动性抗体介导的排斥反应（active AMR，aAMR）；移植后新生DSA（denovo DSA，dnDSA）与晚期AMR、慢性活动性抗体介导的排斥反应（chronic active AMR，caAMR）和 …

Highest mean fluorescent intensity (MFI) donor-specific antibody (DSA) for (A) preformed class I (mean MFI 4075 vs. 1027), (B) preformed class II (mean MFI 2849 vs. 1209), (C) post-OLT class I (mean MFI 1858 vs. 600) and (D) post-OLT class II (mean MFI 9930 vs. 3637). + represents each patient’s maximum value, line represents the group’s ...

单抗原微珠法检测DSA的水平采用MFI值来表示，但不同移植中心判读DSA阳性的MFI阈值并不一致。 目前国内、外大部分HLA实验室以MFI值等于1 000作为抗体阳性的判读阈值 [19, 20]，也有一些实验室MFI值大于500即判为阳性 [21, 22, 23]。

Understanding the complexities and limitations of DSA detection techniques is key for making an accurate risk assessment while improving access to transplantation. The goal of this overview is to provide a practical guide for using solid phase assays and crossmatch (XM) testing.

2024年8月30日 · In severe HLA-alloimmune platelet transfusion refractoriness, DSA-MFI sums >10 000 and major-ABO mismatch actionably predict poor 2-hour CCI. Computer-aided histocompatibility ranking to lower DSA-MFI sums may streamline donor …

The presence of donor-specific anti-HLA antibodies (DSA) is associated with a 10-fold increased risk of graft failure in haploidentical stem cell transplantation (haplo-SCT). Consensus guidelines from the European Society for Blood and Marrow Transplantation set a mean fluorescence intensity (MFI) & …

4 天之前 · In the high DSA group, two patients received a DSA-depleting intervention. Only one patient with an MFI of 5832 (without intervention) developed primary graft failure, while the remaining seven achieved engraftment.

2024年6月1日 · Exposure to alloantigen, including human leukocyte antigen (HLA), results in the production of donor-specific antibodies (DSA). There are limited data about low levels of mean fluorescence intensity (MFI) DSA, especially post-transplantation. This study evaluated allograft outcomes in KT patients with low MFI DSA.

Donor-specific antibodies (DSAs) identified before kidney transplant (preformed DSAs) can cause early rejection, such as hyperacute rejection, accelerated acute rejection, early acute antibody-mediated rejection, and graft loss (1 – 6).